点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 国内手术机器人行业起步较晚，市场长期由外资品牌主导。随着《立项指南》的发布、叠加"大规模设备 更新"政策红利延续、国产设备性价比优势凸显，我们认为手术机器人行业渗透率将加速提升；本土设备 在二三线医院及基层市场的教育成效显著，国产替代确定性强。以腔镜手术机器人为例，随着国产龙头企 业产能释放及临床数据验证成熟，达芬奇的垄断格局正在被逐步重塑。据RoboticTech统计，2025年腔镜 手术机器人中标量方面，国产品牌首次实现对进口品牌的反超，达芬奇的市场份额进一步被压缩，微创、 精锋、思哲睿、术锐等国产品牌中标量持续攀升，市场格局从"单极垄断"迈向"多强竞争"。 "十四五"配置证发放收官，叠加设备更新政策，行业招标装机 ...

Core Viewpoint - Jingfeng Medical, a leading Chinese surgical robot company, successfully listed on the Hong Kong Stock Exchange, becoming the third domestic surgical robot enterprise to go public, with a strong opening performance and significant market capitalization [1][3]. Group 1: IPO and Market Performance - Jingfeng Medical issued a total of 27.72 million H-shares at a price of HKD 43.24 per share, with the opening price reaching HKD 59, reflecting a 28.12% increase and a market capitalization of HKD 21.48 billion [1]. - The company has achieved substantial revenue growth, with projected revenues of RMB 0.48 billion, RMB 1.60 billion, and RMB 1.49 billion for 2023, 2024, and the first half of 2025, respectively, indicating year-on-year growth rates of 233.03% and 393.91% [5]. Group 2: Technological Advancements - Jingfeng Medical is the first in China and the second globally to master both multi-port and single-port laparoscopic surgical robot technologies, successfully replacing the Da Vinci robot in the domestic market [3]. - The company's multi-port laparoscopic surgical robot has been registered in 14 jurisdictions worldwide, including Europe, Asia-Pacific, the Middle East, Africa, and South America [3]. Group 3: Revenue Composition and Global Expansion - In the first half of 2025, surgical robot sales accounted for 92.9% of Jingfeng Medical's revenue, with international markets contributing nearly 40% of total revenue [5][12]. - The company has established a strong presence in the EU market, with revenues from this region reaching RMB 24.32 million, representing 16.3% of total revenue [5]. Group 4: Competitive Positioning - Jingfeng Medical's pricing strategy positions its multi-port laparoscopic surgical robot at approximately RMB 15 million, which is 30%-50% cheaper than the Da Vinci Xi system, while maintaining comparable precision and performance [8][9]. - The company has set up training centers in major Chinese cities and plans to expand globally, aiming to enhance its competitive edge against established players like Intuitive Surgical [11]. Group 5: Future Prospects - Jingfeng Medical is expected to break even by 2026, with a significant reduction in losses from RMB 2.13 billion in 2023 to RMB 890.87 million in the first half of 2025, alongside increasing gross profits [5]. - The company is actively pursuing market entry in Japan and South Korea, with plans to submit registration applications in early 2026, targeting further growth in these regions [15].

Core Insights - Guangzhou Aimuyi Technology Co., Ltd. has successfully broken the international technology monopoly in the surgical robot market with its independently developed near-infrared optical positioning system, electromagnetic positioning system, and surgical robot software platform [1][6][10] - The company has established itself as a core technology supplier in the upstream of the domestic surgical robot industry chain, promoting the localization of core components and contributing to the digital and intelligent upgrade of the medical robot industry [1][6] Company Development - Founded in 2017, Aimuyi is a national high-tech enterprise that utilizes a collaborative innovation model of "industry-university-research-application" to achieve core component localization [1][2] - The founder, Professor Yang Rongqian, emphasizes the complexity and lengthy process of transforming scientific research results into industrial applications, which requires collaboration across multiple fields [2][4] Technological Advancements - Aimuyi's team has over 20 years of experience in optical positioning, electromagnetic positioning, and surgical robots, successfully developing China's first near-infrared optical positioning system in 2019, which has reached an internationally advanced level [4][7] - The optical positioning system's performance is influenced by various factors, including positioning algorithms, hardware design, material selection, and optical imaging technology [4][7] Market Positioning - Aimuyi has built a closed-loop ecosystem of "technology supply-demand feedback-iterative optimization," addressing the long-standing reliance on imported core components in surgical robots [6][10] - The company has established deep collaborations with over 100 medical device manufacturers, with applications in orthopedics, neurosurgery, dentistry, and expanding into specialized fields like transcranial magnetic stimulation and radiation therapy [6][10] Innovation and Collaboration - The company employs a full-chain innovation model, ensuring technological autonomy and control over core components, which is crucial for advancing China's surgical robot industry [7][10] - Aimuyi collaborates with upstream precision processing companies and downstream clinical institutions to refine common needs and guide research directions [7][10] Global Strategy - To navigate international patent barriers, Aimuyi adopts a "local cooperation + overall solution export" strategy, establishing a unique market position in niche areas [10][12] - The company has successfully exported products to Europe, America, and Africa, leveraging domestic policies that favor the development of the surgical robot industry [10][12] Standardization Efforts - Aimuyi is transitioning from a general positioning system to specialized applications, developing a "platform + customization" strategy to meet diverse industry needs [12] - The company is actively leading the establishment of interface protocol standards for surgical robots, which is essential for the industry's future development [12][13]